Literature DB >> 24903472

A case of linear atrophoderma of Moulin successfully treated with methotrexate.

Anissa Zaouak1, Houda Hammami Ghorbel, Rym Benmously-Mlika, Wafa Koubaa, Talel Badri, Samy Fenniche, Insaf Mokhtar.   

Abstract

Linear atrophoderma of Moulin is an acquired rare and self-limited skin condition. It is characterized by atrophic bandlike skin lesions that often show hyperpigmentation and always follow the lines of Blaschko. Usually it begins in childhood or adolescence and there is no evidence of any long term progression. We describe a case of a 21-year-old woman with clinical and histological features of linear atrophoderma of Moulin. The patient was successfully treated with methotrexate 20 mg/week during 6 months with an improvement of skin pigmentation and atrophy. Approximately, 30 cases of linear atrophoderma of Moulin were described in the literature. There is not a proven effective treatment of this dermatosis. High dose penicillin, topical corticosteroids, heparin, and oral potassium aminobenzoate have been used but found to be uneffective. To our knowledge, this is the first case of extensive linear atrophoderma of Moulin treated with methotrexate.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  linear atrophoderma; methotrexate; treatment

Mesh:

Substances:

Year:  2013        PMID: 24903472     DOI: 10.1111/dth.12099

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  3 in total

1.  Linear atrophoderma of Moulin: an underrecognized entity.

Authors:  Omid Zahedi Niaki; Wendy Sissons; Van-Hung Nguyen; Ramin Zargham; Fatemeh Jafarian
Journal:  Pediatr Rheumatol Online J       Date:  2015-10-06       Impact factor: 3.054

2.  Linear atrophoderma of Moulin.

Authors:  Siew-Kiang Tan; Yong-Kwang Tay
Journal:  JAAD Case Rep       Date:  2016-01-08

3.  Linear Atrophoderma of Moulin over Face: An Exceedingly Rare Entity.

Authors:  Ivoreen Darung; Olympia Rudra; Ayan Samanta; Megha Agarwal; Arghyaprasun Ghosh
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.